Cholinergic systems in progressive supranuclear palsy

Brain

Volumn 128, Issue 2, 2005, Pages 239-249

  Warren, Naomi M ^a,b   Piggott, M A ^a   Perry, E K ^a   Burn, D J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Basal ganglia; Cholinergic; Progressive supranuclear palsy

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; PHYSOSTIGMINE; TAU PROTEIN;

BASAL GANGLION; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG TARGETING; GAZE PARALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTERNEURON; MEYNERT BASAL NUCLEUS; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROCHEMISTRY; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; QUALITY OF LIFE; REVIEW;

EID: 13544255426     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh391     Document Type: Review

References (112)

1. Akaike A, Tamura Y, Yokota T, Shimohama S, Kiraura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res 1994; 644: 181-7.
2. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci 2001; 24: 347-53.
3. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-81.
4. Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 1998; 65: 155-63.
5. Atack JR, Litvan I, Thal LJ, May C, Rapoport SI, Chase TN. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. J Neurol Neurosurg Psychiatry 1991; 54: 832-5.
6. Bedard MA, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome. Brain Cogn 1999; 40: 289-313.
7. Bernard V, Normand E, Bloch B. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 1992; 12: 3591-600.
8. Birdi S, Rajput AH, Fenton M, Donat JR, Rozdilsky B, Robinson C, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002; 17: 1255-64.
9. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997a; 54: 465-73.
10. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997b; 11 Suppl 4: S16-22.
11. Bosboom JL, Stoffers D, Wolters E. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 2004; 111: 1303-15.
12. Brandel JP, Hirsch EC, Hersh LB, Javoy-Agid F. Compartmental ordering of cholinergic innervation in the mediodorsal nucleus of the thalamus in human brain. Brain Res 1990; 515: 117-25.
13. Brandel JP, Hirsch EC, Malessa S, Duyckaerts C, Cervera P, Agid Y. Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy. Neuroscience 1991; 41: 25-31.
14. Brenneis C, Seppi K, Schocke M, Benke T, Wenning GK, Poewe W. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004; 75: 246-9.
15. Burn D, Warren N. Towards future therapies in progressive supranuclear palsy. Mov Disord 2005. In press.
16. Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci 2000; 23: 120-6.
17. Carpenter MB, Harbison JW, Peter P. Accessory oculomotor nuclei in the monkey: projections and effects of discrete lesions. J Comp Neurol 1970; 140: 131-54.
18. Cavada C, Company T, Hernandez-Gonzalez A, Reinoso-Suarez F. Acetylcholinesterase histochemistry in the macaque thalamus reveals territories selectively connected to frontal, parietal and temporal association cortices. J Chem Neuroanat 1995; 8: 245-57.
19. Charpantier E, Barneoud P, Moser P, Besnard F, Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport 1998; 9: 3097-101.
20. Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey IW. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1998; 1: 35-44.
21. Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 2001; 8: 573-7.
22. Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, Stuart GW, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 2002; 125: 789-800.
23. Court J, Clementi F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord 1995; 9 Suppl 2: 6-14.
24. Court JA, Piggott MA, Lloyd S, Cookson N, Ballard CG, McKeith IG, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 2000; 98: 79-87.
25. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993; 50: 873-80.
26. Davie CA, Barker GJ, Machado C, Miller DH, Lees AJ. Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 1997; 12: 767-71.
27. Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord 1999; 14: 1011-3.
28. Eidelberg D, Dhawan V. Can imaging distinguish PSP from other neurodegenerative disorders? Neurology 2002; 58: 997-8.
29. Fabbrini G, Barbanti P, Bonifati V, Colosimo C, Gasparini M, Vanacore N, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand 2001; 103: 123-5.
30. Federico F, Simone IL, Lucivero V, De Mari M, Giannini P, Iliceto G, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997a; 62: 239-42.
31. Federico F, Simone IL, Lucivero V, Iliceto G, De Mari M, Giannini P, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders. Mov Disord 1997b; 12: 903-9.
32. Fisher A, Brandeis R, Karton I, Pittel Z, Gurwitz D, Haring R, et al. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3′)quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J Pharmacol Exp Ther 1991; 257: 392-403.
33. Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989; 39: 257-61.
34. Frattali CM, Sonies BC, Chi-Fishman G, Litvan I. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study. Dysphagia 1999; 14: 165-8.
35. Genis I, Fisher A, Michaelson DM. Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment. J Neurochem 1999; 72: 206-13.
36. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 1993; 16: 460-5.
37. Goedert M. Tau protein and neurodegeneration. Semin Cell Dev Biol 2004; 15: 45-9.
38. Grafman J, Litvan I, Stark M. Neuropsychological features of progressive supranuclear palsy. Brain Cogn 1995; 28: 311-20.
39. Graveland GA, DiFiglia M. The frequency and distribution of medium-sized neurons with indented nuclei in the primate and rodent neostriatum. Brain Res 1985; 327: 307-11.
40. Ince E, Ciliax BJ, Levey AI. Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 1997; 27: 357-66.
41. Ishikawa A, Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J Neurol Sci 1993; 117: 28-32.
42. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997; 349: 1805-9.
43. Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1988; 51: 540-3.
44. Juncos JL, Hirsch EC, Malessa S, Duyckaerts C, Hersh LB, Agid Y. Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology 1991; 41: 25-30.
45. Kasashima S, Oda Y. Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and cortico-basal degeneration. Acta Neuropathol 2003; 105: 117-24.
46. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn 2000; 43: 274-82.
47. Kertzman C, Robinson DL, Litvan I. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 1990; 47: 1346-50.
48. Koliatsos VE, Clatterbuck RE, Nauta HJ, Knusel B, Burton LE, Hefti FF, et al. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann Neurol 1991; 30: 831-40.
49. Lachowicz JE, Duffy RA, Ruperto V, Kozlowski J, Zhou G, Clader J, et al. Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788. Life Sci 2001; 68: 2585-92.
50. Landwehrmeyer B, Palacios J. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm Suppl 1994; 42: 229-46.
51. Lemay S, Blanchet P, Chouinard S, Masson H, Soland V, Bedard MA. Poor tolerability of a transdermal nicotine treatment in Parkinson's disease. Clin Neuropharmacol 2003; 26: 227-9.
52. Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 31-9.
53. Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 2002; 1: 423-31.
54. Litvan I, Hutton M. Clinical and genetic aspects of progressive supranuclear palsy. J Geriatr Psychiatry Neurol 1998; 11: 107-14.
55. Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 1989; 26: 404-7.
56. Litvan I, Berrettini WH, Atack JR, Chase TN. CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy. Acta Neurol Scand 1992; 86: 204-6.
57. Litvan I, Blesa R, Clark K, Nichelli P, Atack JR, Mouradian MM, et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994; 36: 55-61.
58. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996a; 47: 1-9.
59. Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996b; 47: 1184-9.
60. Litvan I, Phipps M, Pharr V, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001; 57: 467-73.
61. Londos E, Passant U, Risberg J, Gustafson L, Brun A. Contributions of other brain pathologies in dementia with lewy bodies. Dement Geriatr Cogn Disord 2002; 13: 130-48.
62. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11 (Suppl 1): 11-8.
63. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49: 279-88.
64. Malessa S, Hirsch EC, Cervera P, Javoy-Agid F, Duyckaerts C, Hauw JJ, et al. Progressive supranuclear palsy: loss of choline-acetyltransferase-like immunoreactive neurons in the pontine reticular formation. Neurology 1991; 41: 1593-7.
65. Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 2000; 427: 19-30.
66. Nandi D, Aziz TZ, Giladi N, Winter J, Stein JF. Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. Brain 2002a; 125: 2418-30.
67. Nandi D, Liu X, Winter JL, Aziz TZ, Stein JF. Deep brain stimulation of the pedunculopontine region in the normal non-human primate. J Clin Neurosci 2002b; 9: 170-4.
68. Nandi D, Stein JF, Aziz TZ. Exploration of the role of the upper brainstem in motor control. Stereotact Funct Neurosurg 2002c; 78: 158-67.
69. Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: A clinical cohort study. Neurology 2003; 25: 910-6.
70. Nordberg A, Hellstrom-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 2002; 81: 655-8.
71. Oorschot DE. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J Comp Neurol 1996; 366: 580-99.
72. Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson's disease. Brain 2000; 123: 1767-83.
73. Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B, Hirsch EC. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res 2003; 984: 224-32.
74. Pascual J, Figols J, Grijalba B, Gonzalez AM, del Olmo E, Berciano J, et al. Changes in aminergic receptors in a PSP postmortem brain: correlation with pathological findings. J Neural Transm Suppl 1994; 42: 247-60.
75. Perry EK. Nerve growth factor and the basal forebrain cholinergic system: a link in the etiopathology of neurodegenerative dementias? Alzheimer Dis Assoc Disord 1990; 4: 1-13.
76. Perry EK, Smith CJ, Court JA, Perry RH. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J Neural Transm Park Dis Dement Sect 1990; 2: 149-58.
77. Pfaffenbach DD, Layton DD Jr, Kearns TP. Ocular manifestations in progressive supranuclear palsy. Am J Ophthalmol 1972; 74: 1179-84.
78. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998; 391: 173-7.
79. Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 2004; 29: 108-16.
80. Pisani A, Bonsi P, Centonze D, Gubellini P, Bernardi G, Calabresi P. Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors. Neuropharmacology 2003; 45: 45-56.
81. Quik M, Bordia T, Forno L, McIntosh JM. Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum. J Neurochem 2004; 88: 668-79.
82. Rinne JO, Myllykyla T, Lonnberg P, Marjamaki P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res 1991; 547: 167-70.
83. Rosenberg MB, Friedmann T, Robertson RC, Tuszynski M, Wolff JA, Breakefield XO, et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 1988; 242: 1575-8.
84. Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, LHeureux R, Hauw JJ, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985; 18: 523-9.
85. Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I, Fisher A. Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 1996; 66: 877-80.
86. Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697-702.
87. Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003; 60: 922-7.
88. Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 1999; 46: 62-9.
89. Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol 2000; 48: 194-200.
90. Shinotoh H, Namba H, Yamaguch M. In vivo mapping of brain cholinergic function in Parkinson's disease and progressive supranuclear palsy. Parkinson's disease. Adv Neurol 2001; 86: 249-55.
91. Soliveri P, Monza D, Paridi D, Carella F, Genitrini S, Testa D, et al. Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2000; 69: 313-8.
92. Sovago J, Dupuis DS, Gulyas B, Hall H. An overview on functional receptor autoradiography using [35S]GTPgammaS. Brain Res Brain Res Rev 2001; 38: 149-64.
93. Steele JC. Progressive supranuclear palsy. Brain 1972; 95: 693-704.
94. Suzuki M, Desmond TJ, Albin RL, Frey KA. Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology 2002; 58: 1013-8.
95. Tagliavini F, Pilleri G, Gemignani F, Lechi A. Neuronal loss in the basal nucleus of Meynert in progressive supranuclear palsy. Acta Neuropathol (Berl) 1983; 61: 157-60.
96. Tagliavini F, Pilleri G, Bouras C, Constantinidis J. The basal nucleus of Meynert in patients with progressive supranuclear palsy. Neurosci Lett 1984; 44: 37-42.
97. Taylor P, Brown J. Acetylcholine. In: Siegel GJ, editor. Basic neurochemistry. Molecular, cellular and medical aspects. Philadelphia (PA): Lippincott, Williams and Wilkins; 1999. p. 213-43.
98. Tedeschi G, Litvan I, Bonavita S, Bertolino A, Lundbom N, Patronas NJ, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997; 120: 1541-52.
99. Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group. Neurology 2000; 54: 421-6.
100. Utsuki T, Shoaib M, Holloway HW, Ingram DK, Wallace WC, Haroutunian V, et al. Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat. J Alzheimers Dis 2002; 4: 405-15.
101. Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord 1998; 12: 304-12.
102. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001; 57: 1032-5.
103. Villares J, Strada O, Faucheux B, Javoy-Agid F, Agid Y, Hirsch EC. Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease. Neurosci Lett 1994; 182: 59-62.
104. Wakabayashi K, Takahashi H. Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration. Neuropathology 2004; 24: 79-86.
105. Weiner DM, Levey AI, Brann MR. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 1990; 87: 7050-4.
106. Whitehouse PJ, Kellar KJ. Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders. J Neural Transm Suppl 1987; 24: 175-82.
107. Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, et al. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 1988; 45: 722-4.
108. Williams DR, Paviour DC, Watt HC, Lees AJ. Characteristics of two distinct clinical phenotypes observed in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Mov Disord 2004; 19: S328-9.
109. Wu K, Meyers CA, Bennett JA, King MA, Meyer EM, Hughes JA. Polyethylenimine-mediated NGF gene delivery protects transected septal cholinergic neurons. Brain Res 2004; 1008: 284-7.
110. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002; 53: 590-605.
111. Zhou FM, Wilson C, Dani JA. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 2003; 9: 23-36.
112. Zweig RM, Whitehouse PJ, Casanova MF, Walker LC, Jankel WR, Price DL. Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 1987; 22: 18-25.